Skip to main content
. 2019 May 16;116(23):11309–11318. doi: 10.1073/pnas.1818820116

Fig. 4.

Fig. 4.

Immunofluorescence localization of PLK4 to centrosomes, cleavage furrow, and midbody is altered compared with control (A, DMSO) by treatment with MG-115 protease inhibitor (A, MG115), CFI-400945 PLK4 kinase inhibitor (B, CFI-945), or both (B, CFI-945/MG115). Identification of PLK4 localization to centrosomes (A, DMSO, arrow) is improved by higher magnification (C) to illustrate size difference between centrosomes (arrows) and (substantially larger) midbodies. (D) PLK4 localization to midbodies is confirmed by colocalization with mitotic kinesin-like protein-1 (MKLP-1), a midbody protein. (E) Relative distribution of PLK4 to centrosomes and midbodies with DMSO, MG115, CFI-945, or MG115 and CFI945 treatment. Additional descriptive details are provided in the legend to SI Appendix, Fig. S4.